News | News By Subject | News by Disease News By Date | Search News

Lung cancer News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AstraZeneca PLC (AZN) Loses $10 Billion in Value as Long-Awaited MYSTIC Trial Disappoints     7/27/2017
Roche (RHHBY) Reprioritizes Pipeline, Kicks Leukemia and Lung Cancer Drug Med Back to ORYZON Genomics     7/21/2017
AstraZeneca PLC (AZN) Stock Hits 2017 High as Lung Cancer Med Reduces Death Risk in Phase III Study     5/15/2017
Catastrophic Year for Bay Area's OncoMed (OMED) Continues as Lead Drug Comes Crashing Down in Phase II Study     5/9/2017
Takeda (TKPYY)'s $5 Billion Bet on Ariad (ARIA) Pays Off With Accelerated Approval of Lung Cancer Med     5/1/2017
The FDA Calls Pfizer (PFE)’s Next-Generation Lung Cancer Drug a Breakthrough     4/28/2017
AstraZeneca PLC (AZN)'s Lung Cancer Trial Gets Delayed     4/27/2017
When It Rains, It Pours: Bay Area's OncoMed (OMED) Tanks Again as Lung Cancer Med Fails Phase II, Discontinues Phase I Study     4/18/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline     3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals     3/22/2017
Genentech (RHHBY)'s $94,000-a-Year Drug Tarceva: Why Faster FDA Approvals Could Backfire     2/8/2017
The 7 Worst Clinical Disasters of 2016     12/27/2016
Concordia (CXR.TO) Kills Phase III Trial, Terminates Contract Sales, and Leaves Nasdaq Biotech Index     12/19/2016
Bristol-Myers Squibb (BMY) Looks Over Its Shoulder as Opdivo Disappoints While Merck & Co. (MRK)'s Keytruda Shines in Lung Cancer Study     10/10/2016
Genentech (RHHBY)’s Lung Cancer Drug Alecensa Gets 2nd FDA Breakthrough Status     10/5/2016

News from Around the Web
Investors Take Options Cover Ahead Of AstraZeneca PLC (AZN)'s Much-Anticipated Cancer Trial Data     6/28/2017
How Did Bristol-Myers Squibb (BMY) Lose An Edge In Lung Cancer? It's No Mystery, Says New R&D Boss     6/5/2017
New Blood Test Could Treat Non-Small-Cell Lung Cancer Faster, The Journal of Molecular Diagnostics Reveals     4/19/2017
Sought-After Tesaro (TSRO) Sees A $5 Billion Opportunity For Its Cancer Drug     2/17/2017
Liquid Biopsy For Lung Cancer Provides Rapid Results At Low Cost And No Trauma, Stanford University Study     1/6/2017
Czech Scientists Develop Human Lung Model To Aid Treatments, Brno University Of Technology Study     11/29/2016
Balance Of Power Shifts With Merck & Co. (MRK)'s Keytruda First-Line Therapy Approval In Lung Cancer     10/26/2016
Genentech (RHHBY)’s Tecentriq Wins Second Approval of the Year, This Time for Lung Cancer     10/19/2016
AI Beats Doctors At Visual Diagnosis, Observes Many Times More Lung Cancer Signals, Stanford University Study     8/19/2016
Transgenomic, Inc. (TBIO) Launches First Commercially Available CLIA Test For Detection Of EGFR C797S Mutations That Predict Resistance To 3rd Generation Kinase Therapies For Lung Cancer     7/25/2016
University of Louisville Teams Up With Company To Help Lung Cancer Diagnosis     6/15/2016
This Diet Ups Your Lung Cancer Even If You Don't Smoke, MD Anderson Cancer Center Study     3/9/2016
Biotech Startup Yihuo Bio To Produce New Device For Early Detection Of Lung Cancer     2/29/2016
Could A Lung Cancer Drug Work Better With Coke? Erasmus MC Study     2/16/2016
This Lung Cancer Drug May Not Be What It Seems, Chemists Say     1/4/2016

Press Releases
Pfizer (PFE) Announces Positive Top-Line Results From The Comparative REFLECTIONS B7391003 Study For PF-06439535, A Potential Biosimilar To Avastin 1 (Bevacizumab)     7/24/2017
OncoCyte Analytical Validation Study Of Its Lung Cancer Diagnostic Test Confirms Previously Published Results     7/24/2017
Biothera Announces Initiation Of Phase Ib/II Clinical Study Evaluating Combination Of Imprime PGG And Merck & Co. (MRK)’s KEYTRUDA In Non-Small Cell Lung Cancer     7/19/2017
Ascentage Pharma Approved To Start China Trial Of Apoptosis Drug     7/19/2017
China FDA Approves CTAs For BeyondSpring’s Second Global Plinabulin Registrational Trial For Chemotherapy-Induced Neutropenia Prevention     7/6/2017
Novartis AG (NVS) Receives EU Approval For First-Line Use Of Zykadia In ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)     6/29/2017
MabVax Therapeutics Commences Patient Dosing In MVT-1075 Radioimmunotherapy Phase I Clinical Trial For The Treatment Of Pancreatic, Colon And Lung Cancers     6/27/2017
Cancer Genetics (CGIX) Launches FDA-Approved Universal Companion Diagnostic For Lung Cancer Leveraging Thermo Fisher Scientific (TMO)'s Next Generation Sequencing Panel Oncomine Dx Target Test     6/27/2017
OSE Immunotherapeutics Announces Temporary Pause Of Patient Accrual While Continuing Treatment For Patients Already Enrolled In Phase III Clinical Trial Of Tedopi In Advanced Lung Cancer     6/26/2017
Epizyme (EPZM) Expands Clinical Collaboration To Study Tazemetostat And TECENTRIQ Combination In NSCLC     6/26/2017
BerGenBio AS Awarded NOK 24 Million From Innovasjon Norge To Support The Clinical Development Of BGB324 In Combination With KEYTRUDA For Advanced Lung Cancer     6/26/2017
Novartis AG (NVS) Combination Targeted Therapy Tafinlar + Mekinist Receives FDA Approval For BRAF V600E Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)     6/23/2017
FDA Approves Thermo Fisher Scientific (TMO)'s First Companion Diagnostic Test to Screen Multiple Non-Small Cell Lung Cancer Therapies     6/23/2017
GENFIT (ALGFT) Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH     6/23/2017
Elekta Release: New Data From The Elekta Lung Research Group Support The Use Of Stereotactic Body Radiation Therapy In Elderly Patients With Early-Stage Lung Cancer     6/15/2017

//-->